At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 134,476 enrolled
Drug / intervention
Influenza vaccinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia, Spain
In Brief
A Phase 4 clinical trial evaluating Influenza vaccine for Influenza. Completed, enrolled 134,476 participants across 1 site.
Detailed Summary
This pragmatic randomized trial is designed to evaluate the relative vaccine effectiveness of QIV-HD vs. QIV-SD in reducing the risk of hospitalization for influenza or pneumonia in adults 65-79 years of age in Galicia during 2023/2024 and 2024/2025 seasons.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesSpain
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
Enrollment StartOct 2023
First PostedNov 2023
Primary CompletionMay 2025
TodayJul 2026
First PostedNov 21, 2023
Enrollment StartOct 26, 2023
Primary CompletionMay 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 2.6 years ago
Interventions
Influenza vaccinedrug
Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial